HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates

BACKGROUND: There has been substantial interest in HER2 intratumoral heterogeneity as an explanation for the development of resistance to anti-HER2 therapies in breast cancer, particularly to trastuzumab emtansine (T-DM1). METHODS: Through a literature-based approach, we discuss mechanisms of resist...

Descripción completa

Detalles Bibliográficos
Autores principales: Ocaña, Alberto, Amir, Eitan, Pandiella, Atanasio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6995165/
https://www.ncbi.nlm.nih.gov/pubmed/32005279
http://dx.doi.org/10.1186/s13058-020-1252-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6995165/
https://www.ncbi.nlm.nih.gov/pubmed/32005279
http://dx.doi.org/10.1186/s13058-020-1252-7

Ejemplares similares